Regenxbio (RGNX) Tops Q4 EPS by 45c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Pre-Open Stock Movers 02/25: (ONCE) (CMTA) (QURE) Higher; (MDR) (CRON) (NBR) Lower (more...)
February 25, 2019 9:25 AM ESTPre-Open Movers
Spark Therapeutics (NASDAQ: ONCE) 120.9% HIGHER; announced today that it has entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics at a price of $114.50 per share in an all-cash transaction. This corresponds to a total equity value of approximately $4.8 billion on a fully diluted basis, inclusive of approximately $500 million of projected net cash expected at close. The per share price represents a premium of 122 percent to Sparks closing price on Feb. 22, 2019. The merger agreement has been unanimously approved by the boards of both Spark and... More
Evercore ISI Upgrades Regenxbio Inc. (RGNX) to Outperform
February 25, 2019 2:38 AM ESTEvercore ISI analyst Josh Schimmer upgraded Regenxbio Inc. (NASDAQ: RGNX) from In Line to Outperform.
For an analyst ratings summary and ratings history on Regenxbio Inc. click here. For more ratings news on Regenxbio Inc. click here.
Shares of Regenxbio Inc. closed at $46.50 yesterday.
... More